Skip to content

Lupin to Outlicense Psoriasis Drugs II-56

Lupin to Outlicense Psoriasis Drugs II-56 1

Topical Drugs Overview II-4. Table 2: World Psoriasis Drugs Market – Value Sales of. Lupin to Outlicense Psoriasis Drugs II-56. 9. FOCUS ON SELECT PLAYERS II-57. Read more about Lupin to outsource psoriasis drugs on Business Standard. Lupin, one of the top five drug companies in India, is planning to outlicense its new drugs under development to treat psoriasis within six to nine months. Three of the patients were diagnosed with psoriasis vulgaris type II, and seven were diagnosed with psoriasis vulgaris type I.

Lupin to Outlicense Psoriasis Drugs II-56 2The Hyderabad-based company currently supplies DRL oncology drugs in the Indian market. It was also the first company to out-license a molecule, Balaglitazone, to Novo Nordisk in 1997. In FY13, Ranbaxy spent 450 crore, Sun 676 crore and Lupin, 710 crore. Apotex get EU CHMP nod for fligrastim biosimilar for the treatment of neutropenia. Moberg outlicenses China rights for Kerasal Nail to Menarini. Kerasal Nail (Nalox or Emtrix in certain markets) is a non-prescription product for the treatment of discoloured and deformed nails resulting from fungal infection or psoriasis, with a unique mechanism of action that generates visible improvements within 2-4 weeks of treatment.

Inside Dr

Reportlinker Adds Global Psoriasis Drugs Industry